Amyloid blood biomarker detects Alzheimer's disease

Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid (CSF) biomarkers or expensive such as positron emission tomography (PET) scanning. Here, we determine the secondary structure change of amyloid‐β (Aβ) in human blood. This change used as blood amyloid biomarker indicates prodromal AD and correlates with CSF AD biomarkers and amyloid PET imaging in the cross‐sectional BioFINDER cohort. In a further population‐based longitudinal cohort (ESTHER), the blood biomarker detected AD several years before clinical diagnosis in baseline samples with a positive likelihood ratio of 7.9; that is, those who were diagnosed with AD over the years were 7.9 times more likely to test positive. This assay may open avenues for blood screening of early AD stages as a funnel for further more invasive and expensive tests.

• Publication year

  2018

• Venue

  EMBO Molecular Medicine

• Publication date

  2018-04-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.15252/emmm.201708763PMID 29626112PMCID 5938617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High performance plasma amyloid-β biomarkers for Alzheimer’s disease

  2018cited by this paper
• Biomarkers of Alzheimer’s Disease

  2017cited by this paper
• Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

  2017cited by this paper
• Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

  2017cited by this paper
• Amyloid-β-Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer's Disease.

  2016influential reference
• The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

  2016cited by this paper
• An infrared sensor analysing label‐free the secondary structure of the Abeta peptide in presence of complex fluids

  2016influential reference
• Rates of transition between amyloid and neurodegeneration biomarker states and to dementia among non-demented individuals: a population-based cohort study

  2015cited by this paper
• Amyloid biomarkers in Alzheimer's disease.

  2015cited by this paper
• Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

  2015cited by this paper
• Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer’s Disease

  2015cited by this paper
• Tau in physiology and pathology

  2015cited by this paper
• Association between Oxidative Stress and Frailty in an Elderly German Population: Results from the ESTHER Cohort Study

  2015cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014influential reference
• Comparison of the Diagnostic Accuracy of Neuropsychological Tests in Differentiating Alzheimer's Disease from Mild Cognitive Impairment: Can the Montreal Cognitive Assessment Be Better than the Cambridge Cognitive Examination?

  2014cited by this paper
• Plasma phospholipids identify antecedent memory impairment in older adults

  2014cited by this paper
• A Candidate Plasma Protein Classifier to Identify Alzheimer's Disease

  2014cited by this paper
• Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

  2014cited by this paper
• The critical need for defining preclinical biomarkers in Alzheimer's disease

  2014cited by this paper
• The future of blood‐based biomarkers for Alzheimer's disease

  2014cited by this paper
• Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data

  2013cited by this paper
• Self-propagation of pathogenic protein aggregates in neurodegenerative diseases

  2013cited by this paper
• Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing

  2013cited by this paper
• Universal method for protein immobilization on chemically functionalized germanium investigated by ATR-FTIR difference spectroscopy.

  2013cited by this paper
• Aβ Toxicity in Alzheimer's Disease

  2012cited by this paper
• Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

  2012cited by this paper
• Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

  2012cited by this paper
• Brain amyloid imaging--FDA approval of florbetapir F18 injection.

  2012cited by this paper
• The Toxicity of Amyloid β Oligomers

  2012cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Prevalence of Apolipoprotein E4 Genotype and Homozygotes (APOE e4/4) among Patients Diagnosed with Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2011influential reference
• Alzheimer's disease.

  2011cited by this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Transformation of amyloid β(1–40) oligomers into fibrils is characterized by a major change in secondary structure

  2011cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• Gene variations in GSTM3 are a risk factor for Alzheimer's disease.

  2009cited by this paper
• Selection of controls in case-control studies on maternal medication use and risk of birth defects.

  2007cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Functional waters in intraprotein proton transfer monitored by FTIR difference spectroscopy

  2006cited by this paper
• Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group.

  1994cited by this paper
• Users' Guides to the Medical Literature: III. How to Use an Article About a Diagnostic Test: B. What Are the Results and Will They Help Me In Caring for My Patients?

  1994cited by this paper
• Users' guides to the medical literature.

  1993cited by this paper
• Selection of controls in case-control studies. III. Design options.

  1992cited by this paper
• Cerebrospinal fluid.

  1965cited by this paper
• the original work is properly cited.

  year unknowncited by this paper

• An integrated paper-based microfluidic platform for screening of early-stage Alzheimer's disease by detecting Aβ42.

  2025cites this paper
• THE PROGNOSTIC VALUE OF BLOOD PLASMA BIOMARKERS IN ALZHEIMER'S DISEASE IN AN EXPERIMENT: THE REGRESSION ANALYSIS RESULTS

  2025cites this paper
• Comparative assessment of serum dilution and pure samples for Raman-based oral cancer detection: Evaluating dilution rate performance

  2025cites this paper
• Plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive decline

  2025cites this paper
• Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology

  2025cites this paper
• Replacement of a single residue in an antibody abolishes cognate antigen binding, as predicted by theoretical methods

  2025cites this paper
• An immuno-Infrared Sensor detects preclinical Alzheimer's and Parkinson's Disease by misfolding

  2025cites this paper
• Converging Structural Biology and Nanotechnology to Decipher and Target Alzheimer’s Disease: From Atomic Insights to Clinical Translation

  2025cites this paper
• Prognostic Value of A/T/N Biomarkers

  2025cites this paper
• Surrogate Molecular Biomarkers for Poststroke Cognitive Impairment: A Narrative Review.

  2025cites this paper
• Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform

  2025influential citation
• Older Amyloid Beta as a Candidate Blood Biomarker of Early Cognitive Decline in the Elderly—A Preliminary Study

  2025cites this paper
• Roles, Functions, and Pathological Implications of Exosomes in the Central Nervous System

  2025cites this paper
• The Bio‐Hermes Study: Biomarker database developed to investigate blood‐based and digital biomarkers in community‐based, diverse populations clinically screened for Alzheimer's disease

  2024cites this paper
• A Critical Appraisal of Blood-Based Biomarkers for Alzheimer's Disease.

  2024cites this paper
• Synthetic β-sheets mimicking fibrillar and oligomeric structures for evaluation of spectral X-ray scattering technique for biomarker quantification

  2024cites this paper
• Age-related hearing loss: possible associations with Alzheimer’s disease

  2024cites this paper
• An Overview of the Genes and Biomarkers in Alzheimer's Disease.

  2024cites this paper
• Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability

  2024cites this paper
• Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes Using Alzheimer’s Disease Biofluid, PET, Postmortem Pathology Biomarkers, and APOE Genotype

  2024cites this paper
• Alpha-synuclein misfolding as a fluid biomarker for Parkinson's disease and synucleinopathies measured with the iRS platform

  2024cites this paper
• Risk factors for cognitive decline in non-demented elders with amyloid-beta positivity

  2024cites this paper
• Novel β-amyloid PET Imaging Study of [18F]92 in Patients with Cognitive Decline

  2024cites this paper
• Protein fibril aggregation on red blood cells: a potential biomarker to distinguish neurodegenerative diseases from healthy aging

  2024cites this paper
• Atomic force microscopy in the characterization and clinical evaluation of neurological disorders: current and emerging technologies

  2024cites this paper
• Glomerular Hypertrophy and Splenic Red Pulp Degeneration Concurrent with Oxidative Stress in 3xTg-AD Mice Model for Alzheimer’s Disease and Its Exacerbation with Sex and Social Isolation

  2024cites this paper
• Automatic offline-capable smartphone paper-based microfluidic device for efficient biomarker detection of Alzheimer's disease.

  2024cites this paper
• Attitudes and Viewpoints Toward Prevention Trials in Alzheimer’s Disease

  2023cites this paper
• APOE-ε4 genes may accelerate the activation of the latent form of HSV-1 which would lead to a faster progression of AD

  2023cites this paper
• Innovative SALDI mass spectrometry analysis for Alzheimer's disease synthetic peptides detection.

  2023cites this paper
• Ultrasensitive FET biosensor chip based on self-assembled organic nanoporous membrane for femtomolar detection of Amyloid-β

  2023cites this paper
• Evaluating the Clinical Significance of Diazepam Binding Inhibitor in Alzheimer’s Disease: A Comparison with Inflammatory, Oxidative, and Neurodegenerative Biomarkers

  2023cites this paper
• Ultrasensitive FET biosensor chip based on self-assembled organic nanoporous membrane for femtomolar detection of Amyloid-β

  2023cites this paper
• Artificial intelligence–coupled plasmonic infrared sensor for detection of structural protein biomarkers in neurodegenerative diseases

  2023cites this paper
• Boswellic Acids Improve Clinical Cognitive Scores and Reduce Systemic Inflammation in Patients with Mild to Moderate Alzheimer’s Disease

  2023cites this paper
• Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology

  2023influential citation
• Association of Caffeine Consumption and Brain Amyloid Positivity in Cognitively Normal Older Adults

  2023cites this paper
• Protein fibril length in cerebrospinal fluid is increased in Alzheimer’s disease

  2023cites this paper
• Biomarker Detection using Ge3Sb2Te6-based Permittivity-Asymmetric Metasurface

  2023cites this paper
• Predicting amyloid PET and tau PET stages with plasma biomarkers

  2023cites this paper
• Sleep EEG oscillation associations with plasma amyloid-β42 in apneic adolescents: a cross section study

  2023cites this paper
• The China Alzheimer Report 2022

  2022cites this paper
• Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review

  2022cites this paper
• Differences in resting state functional connectivity underlie visuomotor performance declines in older adults with a genetic risk (APOE ε4) for Alzheimer’s disease

  2022cites this paper
• Blood-based biomarkers in Alzheimer’s disease: a mini-review

  2022cites this paper
• Blood Transcript Biomarkers Selected by Machine Learning Algorithm Classify Neurodegenerative Diseases including Alzheimer’s Disease

  2022cites this paper
• Applications of Single-Molecule Vibrational Spectroscopic Techniques for the Structural Investigation of Amyloid Oligomers

  2022cites this paper
• Isotopic N,N-dimethyl leucine tags for absolute quantification of clusterin and apolipoprotein E in Alzheimer's disease.

  2022cites this paper
• Plasma amyloid-beta levels correlated with impaired hepatic functions: An adjuvant biomarker for the diagnosis of biliary atresia

  2022cites this paper
• Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies

  2022cites this paper
• Alzheimer’s disease: Early-Stage Prediction and Classification using Multi-Model Technique

  2022cites this paper
• Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies

  2022cites this paper
• Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years

  2022cites this paper
• Worsening hearing was associated with higher β-amyloid and tau burden in age-related hearing loss

  2022cites this paper
• Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies

  2022cites this paper
• Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAβ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia

  2022cites this paper
• Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years

  2022cites this paper
• Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview

  2022cites this paper
• Potential Protein Blood-Based Biomarkers in Different Types of Dementia: A Therapeutic Overview.

  2022cites this paper
• Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments

  2022cites this paper
• Practical Considerations in the Administration of Aducanumab for the Neurologist

  2021cites this paper
• Biomarcadores en la enfermedad de Alzheimer

  2021cites this paper
• Early-Onset Alzheimer’s Disease: What Is Missing in Research?

  2021cites this paper
• Three-Dimensional Interfacing of Cells with Hierarchical Silicon Nano/Microstructures for Midinfrared Interrogation of In Situ Captured Proteins.

  2021cites this paper
• Diagnose it yourself: will there be a home test kit for Alzheimer's disease?

  2021cites this paper
• Aβ misfolding in blood plasma measured by immuno‐infrared‐sensor as an age‐independent risk marker of Alzheimer's disease

  2021cites this paper
• Extracellular Vesicles: Novel Roles in Neurological Disorders

  2021cites this paper
• Multimodal, label-free fluorescence and Raman imaging of amyloid deposits in snap-frozen Alzheimer’s disease human brain tissue

  2021cites this paper
• Genetic predisposition, Aβ misfolding in blood plasma, and Alzheimer’s disease

  2021cites this paper
• The PrecivityAD™ Test: Accurate and Reliable LC-MS/MS Assays for Quantifying Plasma Amyloid Beta 40 and 42 and Apolipoprotein E Proteotype for the Assessment of Brain Amyloidosis.

  2021cites this paper
• Alzheimer’s Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment

  2021cites this paper
• Detection of Alzheimer’s associated microRNAs using a DNA-based smart reagent

  2021cites this paper
• Association of the inflammation-related proteome with dementia development at older age: results from a large, prospective, population-based cohort study

  2021cites this paper
• Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond

  2021cites this paper
• Uso dos biomarcadores plasmáticos na otimização do diagnóstico precoce do Alzheimer

  2021cites this paper
• Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies.

  2021cites this paper
• Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer’s and other neurodegenerative diseases

  2021cites this paper
• The cognitive dysfunction related to Alzheimer disease or cerebral small vessel disease

  2021cites this paper
• Aβ misfolding in blood plasma is inversely associated with body mass index even in middle adulthood

  2021influential citation
• Dynamic Changes in the Levels of Amyloid-β42 Species in the Brain and Periphery of APP/PS1 Mice and Their Significance for Alzheimer’s Disease

  2021cites this paper
• DNA-Based Smart Reagent for Detecting Alzheimer's Associated MicroRNAs.

  2021cites this paper
• Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies

  2021cites this paper
• Spatial organization of protein aggregates on red blood cells as physical biomarkers of Alzheimer’s disease pathology

  2021cites this paper
• Peptoid Nanosheet-Based Sensing System for the Diagnosis and Surveillance of Amnestic Mild Cognitive Impairment and Alzheimer's Disease.

  2021cites this paper
• Secondary Prevention of Dementia: Combining Risk Factors and Scalable Screening Technology

  2021cites this paper
• CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice

  2021cites this paper
• Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.

  2021cites this paper
• The Levels of Amyloid β-Protein and P181 in Peripheral Blood of Patients with Alzheimer's Disease Combined with Helicobacter pylori Infection and Their Clinical Significance

  2021cites this paper
• China Registry Study on Cognitive Impairment in the Elderly: Protocol of a Prospective Cohort Study

  2021cites this paper
• Blutbasierte Biomarker zur Optimierung der Früh- und Differentialdiagnostik der Alzheimer-Demenz

  2021cites this paper
• ADAM10 as a biomarker for Alzheimer’s disease

  2021cites this paper
• Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer’s Disease

  2020cites this paper
• Method to discriminate amyloids using fluorescent probes.

  2020cites this paper
• Quantitative analysis of human blood serum using vibrational spectroscopy

  2020cites this paper
• Role of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis

  2020cites this paper
• Relevance of biomarkers across different neurodegenerative

  2020cites this paper
• Struktur—Biomarker zur Früherkennung von Morbus Alzheimer

  2020cites this paper
• Amyloid Metabolism and Amyloid-Targeting Blood-Based Biomarkers of Alzheimer’s Disease

  2020influential citation
• Future avenues for Alzheimer's disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.

  2020cites this paper
• A Pilot Study of Urinary Exosomes in Alzheimer’s Disease

  2020cites this paper